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PREDICTORS OF ANTIHISTAMINE PRESCRIPTION IN THE NATIONAL 
AMBULATORY POPULATION WITH ALLERGIC RHINITIS
Patel HK, Goyal RK, Sangani D, Abughosh S
University of Houston, Houston, TX, USA
OBJECTIVES: Antihistamines have been reported to be the most widely used drug 
category in the treatment of allergic rhinitis despite the recommendation to use intra-
nasal steroids (INS) as the ﬁrst line therapy. The purpose of this study was to examine 
the predictors of receiving an antihistamine prescription in ambulatory care setting in 
the United States. METHODS: A retrospective, cross-sectional study of the data from 
National Ambulatory Medical Care Survey (2006, 2007) was performed. Variables 
examined included whether the physician was a primary care physician, age (children: 
0–18 yrs vs adults), gender, race, geographic region, metropolitan statistical area, 
major reason for visit (chronic vs non chronic), insurance status, patient visit status 
and presence of co-morbidity (asthma, nasal polyps, sinusitis and COPD). Allergic 
rhinitis visits were identiﬁed using ICD9-CM codes, and prescribed medications using 
the Multum Lexicon codes. Covariates were selected based upon the Anderson Behav-
ior Model. Descriptive statistics and multivariate logistic regression were carried out 
to identify predictors of receiving an antihistamine prescription. RESULTS: A total of 
40.56 million ambulatory ofﬁce visits were diagnosed with allergic rhinitis. Antihis-
tamines were prescribed in 45.6% (18.52 million) of these visits. Multivariate analysis 
showed that, children suffering from allergic rhinitis were 1.6 times more likely (OR 
1.611, 95% CI 1.067–2.432) to receive a prescription of anti histamines than adult 
patients. Physician specialty, insurance status, geographic region and presence of co-
morbidity were not found to be signiﬁcant predictors of an antihistamine prescription.
CONCLUSIONS: The result of this study suggests that patient’s age is a signiﬁcant 
predictor of antihistamine prescription. This may partly be explained by the intranasal 
route of administration for the recommended ﬁrst line therapy (INS) which may be 
difﬁcult in children. Future research is needed to evaluate other factors like patient 
socioeconomic status and disease severity, which could not be assessed due to data 
limitation.
RESPIRATORY-RELATED DISORDERS – Cost Studies
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PULMONARY REHABILITATION: A BUDGET IMPACT MODEL TO 
EVALUATE HOW POLICY CHANGES WILL IMPACT REIMBURSEMENT 
FROM A MANAGED CARE PERSPECTIVE
Henlyshyn E, Kamal KM
Duquesne University, Pittsburgh, PA, USA
OBJECTIVES: Before January 1, 2010 there was no procedural code for pulmonary 
rehabilitation (PR). The Department of Health and Human Services (DHHS) hypoth-
esizes that Current Procedural Terminology (CPT) codes for cardiovascular rehabilita-
tion (93797, 93798) and Healthcare Common Procedure Coding System (HCPCS) 
codes for respiratory therapy (G0237, G0238) may be utilized to reimburse for PR 
services, since the services are similar in labor and resource utilization. A budget 
impact model was developed to compare the previous PR reimbursement cost with 
the proposed reimbursement cost using new HCPCS code (GXX30) effective from 
January 1, 2010. METHODS: A budget impact model was built using Microsoft Excel 
(1-year time horizon). A 10% sample from IMS Life Link Health Plans Claims was 
used to identify patients who were recipient of PR services as well as cost data for the 
model inputs. A major assumption was that a patient will receive an average of 2.5 
PR sessions/week based on DHHS. Primary and secondary outcomes were savings Per 
Member Per Month (PMPM) and savings per Treated PMPM, respectively. One-way 
sensitivity analyses were conducted to test the robustness of study results and assump-
tions. RESULTS: A total of 69 patients were identiﬁed as recipients of PR services. 
The PR services were reimbursed at a weighted average of $32.24/claim for an average 
of 15.33 minutes/claim. The new HCPCS code (GXX30) will reimburse $22.20 for a 
minimum of 60 minutes. A PR program lasting 6 weeks(average of 2.5 sessions/ week), 
results in a cost savings of $0.86 PMPM based on the new HCPCS code for PR. 
CONCLUSIONS: The changes in coding and reimbursement proposed by DHHS for 
2010 will likely result in a cost savings for Managed Care Organizations to provide 
reimbursement for PR services; however, generation of HCPCS code GXX30 may 
drive utilization for PR services.
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THE IMPACT OF ASTHMA ON HEALTH CARE UTILIZATION AND 
EXPENDITURE OF PEDIATRIC PATIENTS
Song X1, Shenolikar R2, Costa LA3, Anderson J4, Chu BC5
1Thomson Reuters, Cambridge , MA, USA, 2GlaxoSmithkline, RTP, NC, USA, 3Laurie A. 
Costa, Inc, Bolton, MA, USA, 4Thomson Reuters, Ann Arbor, MI, USA, 5Thomson Reuters, 
Santa Barbara, CA, USA
OBJECTIVES: The study objective was to evaluate direct costs associated with pedi-
atric asthmatic patients in the US. METHODS: Asthma patients with ≥1 primary 
asthma diagnosis, or ≥1 asthma diagnosis any level and ≥1 asthma prescription, or ≥2 
asthma diagnoses any level between January 2003 and December 2005 in the Mar-
ketScan® Commercial Database were extracted. Patients were required to be 4–17 
years old and continuously enrolled 12-month before and 12-month post index date 
(ﬁrst asthma diagnosis or medication claim). Patients with evidence of emphysema or 
chronic obstructive pulmonary disease during the study period were excluded. The 
control cohort consisted of patients aged 4–17 years with no asthma claim who met 
the same inclusion/exclusion criteria. An index date was assigned to controls by adding 
a number to January 2003 that was randomly drawn from a pool of days between 
January 2003 and index date for each asthma patient. Propensity score techniques 
were used to match asthma patients to controls based on baseline demographic and 
clinical characteristics. Multivariate regressions were conducted on matched samples 
to estimate the marginal impact of asthma on costs. RESULTS: A total of 91,199 
pediatric asthmatic patients were matched to 91,199 pediatric non-asthmatic patients. 
Compared with matched non-asthmatic patients, asthmatic patients included a slightly 
larger proportion of males, were younger and had lower comorbidity. After multivari-
ate adjustment, asthmatic patients on average incurred $841 more in total medical 
costs, $438 more in outpatient prescriptions, $186 more in outpatient costs, $95 more 
in Emergency Department visits, and $128 more in hospital admissions (all p < 0.001) 
in a year. CONCLUSIONS: Pediatric patients with asthma experienced signiﬁcantly 
greater medical and pharmacy costs than patients without. Understanding disease 
burden for pediatric patients is key to efﬁciently utilizing health management interven-
tions to decrease costs and potentially improve quality of life for both patients and 
caregivers.
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ECONOMIC BURDEN OF ANAPHYLAXIS IN THE UNITED STATES
Patel DA
Virginia Commonwealth University, Richmond, VA, USA
OBJECTIVES: To estimate the direct medical and indirect costs from anaphylaxis in 
the U.S. METHODS: The study assessed the economic burden for anaphylaxis from 
a societal perspective, measuring the costs for the year 2006. Costs were estimated 
using a bottom-up approach—calculating the average cost of illness per patient and 
multiplying it by reported prevalence estimates. Anaphylactic patients with an emer-
gency department (ED), ofﬁce based physician, outpatient, and inpatient visits were 
identiﬁed using ICD-9 codes from federally administered databases, i.e. NHAMCS-
ED, NAMCS, NHAMCS-OPD, and HCUP-NIS respectively. Direct medical costs for 
each patient were estimated by either converting ﬁnal billed charges to cost, or by 
using Medicare reimbursement values. Direct medical costs also included reimburse-
ment values for ambulance, and epinephrine self-injector devices. Indirect costs were 
quantiﬁed by estimating the lost productivity, in terms of lost earnings due to absentee-
ism and mortality, of patients or caregiver. These values were based on the earnings 
estimate from BLS surveys. Prevalence estimates were obtained from published 
literature. RESULTS: The study estimated over 1.1 million patient visits with anaphy-
lactic reactions nationwide. Mean age of the hospitalized patients was 38.9 (±20.9), 
with 56.7% females, and half being Caucasian. Total direct costs were estimated to 
be around $ 500 million, with the major contribution from inpatients admissions 
(34%) and ED visits (33.7%). Costs of $17 million (3.3%) and $41 million (8.2%) 
were incurred from ambulance runs and epinephrine self-injector devices respectively. 
Total indirect costs ($) were around 320 million, with most of the costs (83%) arising 
from absenteeism from work due to the reaction. CONCLUSIONS: Dealing with 
anaphylaxis results in an economic burden close to a billion dollar, with the costs in 
the inpatient and ED setting outweighing the other costs. These numbers are believed 
to be an underestimation due to irregularities in diagnosis and coding of 
anaphylaxis.
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ECONOMIC BURDEN OF EXACERBATIONS IN CHRONIC OBSTRUCTIVE 
PULMONARY DISEASE
Yu A1, Yang H1, Wu EQ1, Dembiski M2, Blum S2, Setyawan J2
1Analysis Group, Inc., Boston, MA, USA, 2Forest Research Institute, Jersey City, NJ, USA
OBJECTIVES: Exacerbations are believed to be a major cost driver in COPD manage-
ment. Exacerbations are episodes of acute worsening of COPD symptoms, including 
cough, sputum production and dyspnea. This study aims to estimate the costs associ-
ated with COPD exacerbations for third-party payers in the United States. METHODS: 
COPD patients were identiﬁed using the MarketScan database (2004–2008). Inclusion 
criteria included ≥2 COPD diagnoses (ICD-9-CM: 490.xx-492.xx, 494.xx-496.xx), 
≥12 months of continuous plan enrollment, ≥40 years of age, and ≥1 exacerbation 
during the study period. The average available period for follow up was 2.89 years. 
Exacerbations were identiﬁed by the use of oral or parenteral corticosteroids within 
7 days of COPD diagnosis. If hospitalization or death occurred, it was classiﬁed as a 
severe exacerbation. The presence of exacerbation-, total-, and COPD-related costs 
was evaluated at quarterly intervals. Costs were inﬂation adjusted to 2008. Quarterly 
cost differences were estimated using generalized estimating equation (GEE) methods, 
controlling for baseline characteristics. RESULTS: A total of 228,978 COPD patients 
were identiﬁed with ≥1 exacerbation during the study period, including 66,680 (29%) 
patients who experienced severe exacerbations. A total of 2,644,174 patient-quarter 
intervals were available for assessment, of which 446,690 patient-quarters included 
an exacerbation: severe: 90,210 (20.2%); non-severe: 356,480, (79.8%). Average cost 
for quarters with exacerbations were $8726 (severe: $17,016; non-severe: $6628) 
compared to $4762 for quarters without exacerbations. Adjusting for baseline char-
acteristics, incremental quarterly costs for exacerbations was $11,261 for severe, 
$1509 for non-severe, and $3439 for any exacerbation over quarters without an 
exacerbation (all P < 0.001). Over half of the total incremental costs were accounted 
for by COPD-related incremental costs: $6116 for severe, $775 for non-severe, and 
$1831 for any exacerbation over quarters without an exacerbation (all P < 0.001). 
CONCLUSIONS: Exacerbations, especially those that are severe, present a signiﬁcant 
economic burden to third-party payers in COPD management.
